find the paper behind the claim
CJC-1295 papers describe tests and leave health questions open
The compound is a research compound tested in people, animals and lab mixtures. Here you can find the original papers on blood changes, sports tests and the unanswered health questions.
The numbers beside findings lead to the papers listed here
CJC-1295 has been studied briefly in people, despite many claims of health gains. This list of papers lets you check what the researchers actually found.
The little numbers beside findings match the numbered papers and public documents below. Each entry includes a link or study number to help you find the original.
In early-2006, Teichman's healthy adults had a 2- to 10-fold growth hormone rise: two to ten times the earlier level [1]. That blood rise wasn't proof of better health.
The liver's growth-related hormone rose too, and blood changes lasted for days. Half the compound left blood within an estimated 5.8-to-8.1-day period.
Another study that year found higher growth hormone without stopping its normal bursts [8]. In two thousand nine, researchers found changes in blood proteins in healthy young men [10].
A study in mice born unable to make a natural growth-starting hormone checked growth [9]. Those animal results don't establish what taking the compound would do for you.
Separate studies tested rat hormones and sports lab methods
In 1986, researchers measured how quickly the original natural hormone left healthy men's blood [6]. Later work tried to make related compounds last longer in blood.
During two thousand five, Jette tested CJC-1295 joined to blood protein in rats [7]. Across two hours, the total hormone measured was 4-fold higher: four times the unattached version's result.
A separate test in lab liquid showed resistance to a protein that normally breaks hormones down. That was a test of breakdown, rather than a treatment test in people.
Two thousand two: related hormone research gave a reason to study two compounds together [15]. That work didn't establish health gains from a specific pair in healthy adults.
In 2010, Henninge identified the compound in an unknown seized product [2]. Later tests found very small amounts of related compounds in human blood [3][4].
Researchers also checked that a test could identify the compound in horse blood [13]. A 2021 review brought together advances in tests for these hormone-raising compounds [5].
The 2025 review covered related hormone-raising compounds and their medical research [12]. Sports rules [14] and 2024 FDA advisers' papers [11] cover bans and pharmacy concerns.
Lab catalogues disagree about the compound's makeup and the weight of one molecule, its smallest unit. That lab weight isn't a shot amount, and the disagreement can't prove safe treatment.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
- Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS. Anal Bioanal Chem. 2016. ↗
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs. Drug Test Anal. 2019. ↗
- Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
- Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. 1986. ↗
- Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing materials on growth-hormone secretagogues including CJC-1295 (2024); CJC-1295 not recommended for the 503A bulk drug substances list. ↗
- Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019. ↗
- World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard, 2025. ↗
- Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced GH secretion. Endocrinology. 2002. ↗
- (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
- Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363(9418):1346-1353 ↗
- (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
- (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
- ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
- Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗